News & Events
The latest press releases and publications from Onco3R Therapeutics.
Stay in the loop with our latest company milestones!
Onco3R Therapeutics Announces Completion of First Multiple Ascending Dose Cohort in Phase 1 Trial of Novel SIK3 inhibitor O3R-5671
Completion of First Multiple Ascending Dose Cohort in Phase 1
Onco3R Therapeutics reports first pre-clinical data from its best-in-class precision oncology portfolio at the 2025 AACR-NCI-EORTC symposium
First pre-clinical data from best-in-class precision oncology portfolio at 2025 AACR-NCI-EORTC symposium
Approval of First Clinical Trial Application for Novel SIK inhibitor O3R-5671 in Autoimmune Diseases
Approval First Clinical Trial Application